Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Buntanetap

Small molecule · developed by Annovis Bio

Phase 3 Most advanced trial

ANVS Developer

1 Registered trials

What is Buntanetap?

Buntanetap (also known as posiphen) is an oral capsule taken once daily at 30 mg.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type: Small molecule
Therapy area: Neurology
Developer: Annovis Bio Inc. (ANVS)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: SUE285UG3S

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06709014	Phase 3	Early Alzheimers Disease	Active not recruiting	ANVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Early Alzheimers Disease

Sources

ClinicalTrials.gov NCT06709014

Updated Oct 11, 2026. Something wrong or missing? Report it on the ANVS page.

Follow ANVS, the company behind Buntanetap

See ANVS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ANVS catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z